Andere Sprachen Tiziana Life Sciences Ltd

Aktien

A3C5SS

BMG889121031

TLSA

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:00 17.05.2024			% 5 Tage	% 1. Jan.
0,744 ^USD	+9,25 %		+19,48 %	+32,86 %

10.05.	Tiziana Life Sciences Ltd. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI
25.04.	Tiziana Life Sciences Ltd. berichtet über positive 3-Monats-Neuroimaging-Ergebnisse bei Patienten mit Multipler Sklerose, die intranasales Foralumab erhalten	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Tiziana Life Sciences Files for Orphan Drug Designation for Intranasal Foralumab	13.05.
Tiziana Life Sciences Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	10.05.
MEDIA: MS News Today: Foralumab found to ease fatigue in SPMS patients in access program	25.04.
Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab	25.04.
Tiziana Life Sciences Ltd Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab	25.04.
Sector Update: Health Care Stocks Rise in Afternoon Trading	23.04.
Tiziana Life Sciences Says US FDA Allows Enrollment of 20 More Patients in Foralumab MS Expanded Access Program	23.04.
Tiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access Program	23.04.
Tiziana Life Sciences, Ltd. Announces FDA Allowance for Additional Twenty Patients to Be Enroll in Intranasal Foralumab Multiple Sclerosis Expanded Access Program	23.04.
Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today	22.04.
Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Program	22.04.
Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in Its Expanded Access Program	22.04.
Tiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology	19.04.
Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today®	19.04.
Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with Pira Highlighted in Neurology	19.04.
Tiziana Life Sciences Ltd. Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology	18.04.
Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology	11.04.
Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer’s Disease	05.03.
Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients	08.01.
Tiziana Life Sciences Ltd. Announces Updated Clinical and Pet Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients	08.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Tiziana Life Sciences Ltd

Aktien

A3C5SS

BMG889121031

TLSA

Andere Sprachen

Filter